[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-study-detail:100629665":3},{"organization":4,"armGroups":7,"interventions":20,"overallOfficials":32,"centralContacts":37,"locations":46,"responsibleParty":209,"collaborators":26,"id":212,"slug":213,"hasResults":214,"nctId":215,"briefTitle":216,"officialTitle":217,"acronym":218,"eligibilityCriteria":219,"healthyVolunteers":214,"sex":220,"minAge":221,"maxAge":26,"enrollmentInfo":222,"targetDuration":26,"studyType":225,"phases":226,"briefSummary":228,"conditions":229,"keywords":235,"overallStatus":67,"whyStopped":26,"lastUpdateSubmitDate":242,"lastUpdatePostDateStruct":243,"startDateStruct":246,"completionDateStruct":248,"leadSponsor":250,"locationsCount":251},{"fullName":5,"class":6},"Sun Yat-sen University","OTHER",[8,15],{"label":9,"type":10,"description":11,"interventionNames":12},"Radiotherapy arm","EXPERIMENTAL","Patients will receive pelvic radiotherapy and androgen deprivation therapy for 2 years.",[13,14],"Drug: Androgen Deprivation Therapy (ADT)","Radiation: radiotherapy",{"label":16,"type":17,"description":18,"interventionNames":19},"ADT arm","ACTIVE_COMPARATOR","Patients will receive androgen deprivation therapy alone for 2 years.",[13],[21,27],{"type":22,"name":23,"description":24,"armGroupLabels":25,"otherNames":26},"DRUG","Androgen Deprivation Therapy (ADT)","Androgen deprivation therapy includes available GnRH agonists and antagonists, such as Triptorelin, Leuprolide, Goserelin and Degarelix. No novel hormonal therapy is allowed.",[16,9],null,{"type":28,"name":29,"description":30,"armGroupLabels":31,"otherNames":26},"RADIATION","radiotherapy","Radiotherapy will be administered using IMRT or VMAT techniques. Radiation fields will include the pelvic lymph node drainage areas, with inclusion of the prostate bed in patients with pT3-4 disease or positive surgical margins.",[9],[33],{"name":34,"affiliation":35,"role":36},"Liru He, PhD","Sun Yat-Sen University Cancer Center","PRINCIPAL_INVESTIGATOR",[38,42],{"name":34,"role":39,"phone":40,"phoneExt":26,"email":41},"CONTACT","+862087343030","helir@sysucc.org.cn",{"name":43,"role":39,"phone":44,"phoneExt":26,"email":45},"Yang Liu, MD","+862087341521","liuyang1@sysucc.org.cn",[47,65,79,89,99,112,125,139,153,166,176,186,196],{"facility":48,"status":49,"city":50,"state":51,"zip":26,"country":52,"countryCode":53,"cosmosGeoPoint":54,"geoPoint":59,"contacts":60},"Dongguan People's Hospital","NOT_YET_RECRUITING","Dongguan","Guangdong","China","CN",{"type":55,"coordinates":56},"Point",[57,58],113.74866,23.01797,{"lat":58,"lon":57},[61],{"name":62,"role":39,"phone":63,"phoneExt":26,"email":64},"Xuefang Zhang, Dr.","+86-0769-28637333","xuefang00000@163.com",{"facility":66,"status":67,"city":68,"state":51,"zip":69,"country":52,"countryCode":53,"cosmosGeoPoint":70,"geoPoint":74,"contacts":75},"Sun Yat-sen University Cancer Center","RECRUITING","Guangzhou","510060",{"type":55,"coordinates":71},[72,73],113.25,23.11667,{"lat":73,"lon":72},[76,77,78],{"name":43,"role":39,"phone":44,"phoneExt":26,"email":45},{"name":34,"role":39,"phone":40,"phoneExt":26,"email":41},{"name":34,"role":36,"phone":26,"phoneExt":26,"email":26},{"facility":80,"status":49,"city":68,"state":51,"zip":26,"country":52,"countryCode":53,"cosmosGeoPoint":81,"geoPoint":83,"contacts":84},"The First Affiliated Hospital of Guangzhou Medical University",{"type":55,"coordinates":82},[72,73],{"lat":73,"lon":72},[85],{"name":86,"role":39,"phone":87,"phoneExt":26,"email":88},"Jiancong Sun, Dr.","+86-20-83337750","sunjiancong@126.com",{"facility":90,"status":49,"city":68,"state":51,"zip":26,"country":52,"countryCode":53,"cosmosGeoPoint":91,"geoPoint":93,"contacts":94},"The First Affiliated Hospital, Sun Yat-sen University",{"type":55,"coordinates":92},[72,73],{"lat":73,"lon":72},[95],{"name":96,"role":39,"phone":97,"phoneExt":26,"email":98},"Yan Wang, Dr.","+86-020-87755766","wangyan7@mail.sysu.edu.cn",{"facility":100,"status":49,"city":101,"state":51,"zip":26,"country":52,"countryCode":53,"cosmosGeoPoint":102,"geoPoint":106,"contacts":107},"Affiliated Hospital of Guangdong Medical University","Zhanjiang",{"type":55,"coordinates":103},[104,105],110.38749,21.23391,{"lat":105,"lon":104},[108],{"name":109,"role":39,"phone":110,"phoneExt":26,"email":111},"Zhennan Wang","+867592387612","zhennan_wang163@163.com",{"facility":113,"status":67,"city":114,"state":115,"zip":26,"country":52,"countryCode":53,"cosmosGeoPoint":116,"geoPoint":120,"contacts":121},"Henan Cancer Hospital","Zhengzhou","Henan",{"type":55,"coordinates":117},[118,119],113.64861,34.75778,{"lat":119,"lon":118},[122],{"name":123,"role":39,"phone":124,"phoneExt":26,"email":26},"Wen Wang, Dr.","+86-400-0371-818",{"facility":126,"status":67,"city":127,"state":128,"zip":26,"country":52,"countryCode":53,"cosmosGeoPoint":129,"geoPoint":133,"contacts":134},"West China Hospital, Sichuan University","Chengdu","Sichuan",{"type":55,"coordinates":130},[131,132],104.06667,30.66667,{"lat":132,"lon":131},[135],{"name":136,"role":39,"phone":137,"phoneExt":26,"email":138},"Yali Shen","+862885422114","sylprecious@163.com",{"facility":140,"status":49,"city":141,"state":142,"zip":26,"country":52,"countryCode":53,"cosmosGeoPoint":143,"geoPoint":147,"contacts":148},"The First Affiliated Hospital, Zhejiang University School of Medicine","Hangzhou","Zhejiang",{"type":55,"coordinates":144},[145,146],120.16142,30.29365,{"lat":146,"lon":145},[149],{"name":150,"role":39,"phone":151,"phoneExt":26,"email":152},"Senxiang Yan","+8657187236413","yansenxiang@zju.edu.cn",{"facility":154,"status":67,"city":155,"state":26,"zip":26,"country":52,"countryCode":53,"cosmosGeoPoint":156,"geoPoint":160,"contacts":161},"Beijing Hospital","Beijing",{"type":55,"coordinates":157},[158,159],116.39723,39.9075,{"lat":159,"lon":158},[162],{"name":163,"role":39,"phone":164,"phoneExt":26,"email":165},"Qiuzi Zhong","+861085132266","drzhongqiuzi@163.com",{"facility":167,"status":49,"city":155,"state":26,"zip":26,"country":52,"countryCode":53,"cosmosGeoPoint":168,"geoPoint":170,"contacts":171},"Cancer Hospital, Chinese Academy of Medical Sciences",{"type":55,"coordinates":169},[158,159],{"lat":159,"lon":158},[172],{"name":173,"role":39,"phone":174,"phoneExt":26,"email":175},"Ningning Lu","+861087787388","Ning-Ning.Lu@hotmail.com",{"facility":177,"status":67,"city":155,"state":26,"zip":26,"country":52,"countryCode":53,"cosmosGeoPoint":178,"geoPoint":180,"contacts":181},"Peking University First Hospital",{"type":55,"coordinates":179},[158,159],{"lat":159,"lon":158},[182],{"name":183,"role":39,"phone":184,"phoneExt":26,"email":185},"Hongzhen Li","+861083572211","hongzhen.li@pkufh.com",{"facility":187,"status":49,"city":155,"state":26,"zip":26,"country":52,"countryCode":53,"cosmosGeoPoint":188,"geoPoint":190,"contacts":191},"Peking University Third Hospital",{"type":55,"coordinates":189},[158,159],{"lat":159,"lon":158},[192],{"name":193,"role":39,"phone":194,"phoneExt":26,"email":195},"Hao Wang","+861082264204","wanghaobysy@bjmu.edu.cn",{"facility":197,"status":49,"city":198,"state":26,"zip":26,"country":52,"countryCode":53,"cosmosGeoPoint":199,"geoPoint":203,"contacts":204},"The First Affiliated Hospital of Naval Medical University","Shanghai",{"type":55,"coordinates":200},[201,202],121.45806,31.22222,{"lat":202,"lon":201},[205],{"name":206,"role":39,"phone":207,"phoneExt":26,"email":208},"Huojun Zhang","+862131166666","chyyzhj@163.com",{"type":36,"investigatorFullName":210,"investigatorTitle":211,"investigatorAffiliation":5,"oldNameTitle":26,"oldOrganization":26},"ZHOU FANGJIAN","Chief Physician","100629665","phase-3-radiotherapy-after-prostatectomy-for-node-positive-prostate-cancer-100629665",false,"NCT07477626","Radiotherapy After Prostatectomy for Node Positive Prostate Cancer","Radiotherapy and Androgen Deprivation Therapy Versus Androgen Deprivation Therapy Alone After Prostatectomy for Node Positive Prostate Cancer (RADVAN): A Multicenter, Randomized Controlled Phase Ⅲ Trial","RADVAN","Inclusion Criteria:\n\n* Age ≥ 18 years.\n* Histologically confirmed adenocarcinoma of the prostate.\n* Radical prostatectomy with pelvic lymph node dissection and pathologically confirmed positive pelvic lymph nodes (AJCC 8th edition: external iliac, internal iliac, obturator, presacral, periprostatic, and\u002For perirectal nodes).\n* ECOG performance status 0-2.\n* Started postoperative GnRH agonist or antagonist therapy for less than 1 year if receiving postoperative androgen deprivation therapy\\*.\n* Adequate major organ function, defined as:\n\nHemoglobin ≥ 90 g\u002FL Platelet count ≥ 75 × 10⁹\u002FL Total bilirubin ≤ 3 × ULN AST or ALT ≤ 5 × ULN\n\n* Use of effective contraception during the study and for 3 months after.\n* Written informed consent provided, with willingness and ability to comply with study visits, treatments, and procedures.\n\n  * Prior postoperative ARAT use ≤ 3 months is eligible after treatment discontinuation.\n\nExclusion Criteria:\n\n* Measurable pelvic recurrence on postoperative MRI or CT (RECIST 1.1, including prostate bed and lymph nodes).\n* Radiographically confirmed distant metastasis (M1a, M1b, or M1c).\n* Neoadjuvant hormonal therapy \\> 3 months before prostatectomy.\n* Malignancy within 5 years that may interfere with study safety or efficacy assessments.\n* Castration-resistant prostate cancer (CRPC) prior to enrollment per 2025 EAU criteria\n* Prior radiotherapy overlapping irradiation fields that may compromise normal tissue.\n* Serious comorbidities affecting study treatment.\n* Psychiatric disorders preventing understanding or compliance.\n* Any condition that, in the investigator's judgment, makes participation unsuitable.","MALE","18 Years",{"count":223,"type":224},372,"ESTIMATED","INTERVENTIONAL",[227],"PHASE3","The goal of this clinical trial is to evaluate whether the addition of pelvic radiotherapy to androgen deprivation therapy (ADT) can delay disease progression and improve survival outcomes in patients with pathologically confirmed regional lymph node-positive (pN1) prostate cancer after radical prostatectomy.\n\nThe main questions it aims to answer are:\n\n* Does ADT combined with pelvic radiotherapy improve biochemical recurrence-free survival (bRFS) compared with ADT alone in pN1 patients?\n* Does the addition of pelvic radiotherapy improve clinical progression-free survival, metastasis-free survival, overall survival, and prostate cancer-specific survival without unacceptable toxicity?\n\nResearchers will compare ADT plus pelvic radiotherapy with ADT alone to see if combined treatment improves disease control and long-term clinical outcomes.\n\nParticipants with positive lymph nodes after prostatectomy will be randomly assigned in a 2:1 ratio to receive ADT plus pelvic radiotherapy, or ADT alone. ADT will be administered for 2 years. Patients with radiologically detectable pelvic recurrence or distant metastases after radical prostatectomy will be excluded. Safety, adverse events, and health-related quality of life will be assessed during follow-up.",[230,231,232,233,234],"Prostate Cancer (Post Prostatectomy)","Radiotherapy; Image-Guided","Prostate Cancer Non-Metastatic","Androgen Deprivation Therapy","Lymph Node Positive",[236,237,238,29,239,240,241],"prostate cancer","node positive","pN1","androgen deprivation therapy","hormone therapy","prostatectomy","2026-06-15",{"date":244,"type":245},"2026-06-16","ACTUAL",{"date":247,"type":245},"2026-03-20",{"date":249,"type":224},"2038-12-31",{"name":5,"class":6},13]